Pharma outsourcing: people on the move

By Nick Taylor

- Last updated on GMT presents its latest round-up of new appointments, employment moves and personnel news in the pharmaceutical contract services sector.

WuXi PharmaTech​ has appointed Steven Hutchins​ as its new vice president of business development.

In this role Hutchins will be responsible for leading the company's global business development, reporting directly to CEO Ge Li.

Hutchins has previously worked as vice president of business development and collaboration management at BioDuro and as director of global basic and preclinical sourcing at Merck.

WuXi is hoping his knowledge of contract research organisations (CRO) and R&D outsourcing will be beneficial to the company.

Shawn Gallagher​ has joined Eisai​ as senior director of outsource manufacturing operations. Gallagher will be based at Eisai’s production and formulation R&D facility in Research Triangle Park, North Carolina.

Prior to joining Eisai Gallagher worked at Catalent Pharma Solutions, taking responsibility for operations related to a new sterile facility and a biologics manufacturing business unit.

US-based CRO Averion​ has appointed Peter Gonze​ as executive vice president of global business development.

In this capacity Gonze will take responsibility for global business development and marketing activities and will serve on the company's executive management team.

Gonze has over 35 years experience in pharmaceutical sales, marketing and development. Most recently Gonze was CEO at Unither Pharmacueticals and has also held positions at GlaxoSmithKline, Johnson & Johnson and Abbott Diagnostics.

Pharmaceutical marketing agency Ignite Health​ has appointed Ann Calandro​ as senior editor at its New Jersey office.

Prior to joining Ignite Calandro held the post of medical editor for MRM Gillespie. Ignite provides contract marketing to more than 350 pharmaceutical, biotech, life sciences and healthcare payor companies, including Roche, Merck & Co, Eli Lilly and Bristol-Myers Squibb.

The Association of Clinical Research Organizations​ (ACRO) has appointed Daniel Perlman​ to its board of directors.

Perlman is CEO of US-based CRO ReSearch Pharmaceutical Services (RPS), which recently joined ACRO at the regular member level. All regular members of ACRO are represented with a seat on the association’s board.

ACRO represents the contract research industry to regulators, biopharmaceutical clients, policy makers and the public, with its board providing leadership in these areas.

Related news

Show more

Related products


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers